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Muco-Obstructive Lung Diseases
To the Editor: The review article by Boucher 
(May 16 issue)1 does not include a discussion of 
asthma as a muco-obstructive lung disease. In a 
subgroup of patients with asthma, clinically sig-
nificant mucus plugging is detected on high-
resolution computed tomographic imaging. This 
condition is characterized clinically by severe 
airf low obstruction and a lack of response to 
both bronchodilators and systemic glucocorti-
coids.2 Mucus-derived obstruction is an impor-
tant asthma phenotype because it may predict 
more persistent obstruction than that which is 
usually encountered and involve a treatment 
 approach that is similar to that for other muco-
obstructive diseases.
Furthermore, overall mucin concentrations 
have been found to be higher both in patients 
with stable asthma and in those with asthma 
exacerbations than in healthy persons, although 
the predominant mucin in patients with asthma 
is MUC5AC,3 and goblet-cell hyperplasia has been 
associated with neutrophilic asthma, which shares 
many similarities with chronic obstructive pul-
monary disease (COPD).4 Finally, hypertonic sa-
line, which is frequently used in patients with 
other muco-obstructive lung diseases, has been 
shown to increase ciliary clearance in patients 
with asthma and is an underused therapy in this 
population.5
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To the Editor: Boucher analyzes mechanistic 
routes that contribute to the pathogenesis of 
muco-obstructive lung diseases, including direct 
biophysical effects and downstream consequences 
of hypoxia-mediated modifications to the micro-
biota. The posited muco-inflammatory cycle re-
sulting from cytokine release by hypoxic, acti-
vated macrophages is noted, but recent research 
findings indicate that a more multifaceted model 
of immune, inflammatory modulation in a high-
mucin environment is warranted.1,2
Mucin hypersecretion not only causes release 
of proinflammatory cytokines but, in the vicious 
cycle of the inflamed lung, is also a consequence 
of inflammatory cytokine release. Overexpression 
of interleukin-8 in the lung causes dramatic up-
regulation of MUC5AC and MUC5B and changes 
to innate and adaptive immune programs that 
both combat infection and drive lung remodel-
ing with damage to epithelial tight junctions.2 
Furthermore, local mucins modulate the func-
tion of dendritic cells, including the set point of 
proinflammatory or antiinflammatory mucosal 
immune recognition of microbiota species.3 We 
think that this aspect of immune programming 
for lung host defense, including changes to anti-
gen recognition of bacterial pathogens observed 
in patients with chronic lung diseases such as 
COPD and bronchiectasis, is important in under-
standing muco-obstructive diseases.1,2,4
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The author replies: Most is correct that asth-
ma can have characteristics of muco-obstruction. 
However, asthma was not included in my article 
because of missing information and differences 
in pathogenesis and phenotypes. First, unfortu-
nately, data on mucus concentrations (particu-
larly total mucin concentrations) in patients with 
asthma are lacking. Second, subgroups of pa-
tients with asthma who have mucus plugging 
typically have type 2 helper T (Th2) cell–high, 
MUC5AC-dominant phenotypes. In contrast, the 
muco-obstructive phenotype is dominated by 
MUC5B, which is regulated by type 17 helper 
T cells and interleukin-1.1 Also, most patients 
with muco-obstructive diseases have persistent 
and high-density bacterial infection with staphy-
lococcus, Haemophilus inf luenzae, and, ultimately, 
pseudomonas; these infections are not typically 
associated with asthma.
We do need a better name than “muco-obstruc-
tive lung diseases.” The initial goal with the use 
of that term was to better group diseases that 
are not adequately described by the term “chronic 
bronchitis.” The term “suppurative muco-obstruc-
tive disease” might be preferred if it is agreed 
that intense eosinophil-dominant inflammation 
is not suppurative. “MUC5B-dominant muco-
obstructive disease” is an option, but data are 
not yet available to indicate whether this name 
distinguishes mild asthma, Th2-low asthma, or 
both from the diseases described in the article.
Finally, hypertonic saline may indeed be a 
useful therapy for asthma. If mucus in a patient 
with asthma proves to be hyperconcentrated, 
and hyperreactivity of the airways is not prob-
lematic, as suggested by Alexis et al.,2 clinical 
trials of hypertonic saline are warranted.
Boyton and Altmann are correct that muco-
obstructive positive-feedback cycles involve not 
only the pathways described in my article but, 
indeed, many more pathways.1 However, the in-
tent of Figure 3 of the article was not to be inclu-
sive but to highlight two key aspects of the 
pathogenesis of this complex disease. First, an 
imbalance between mucin secretion and fluid 
secretion is central to persistent muco-obstruc-
tion. Airway epithelia that respond to proinflam-
matory stimuli with mucin secretion but inade-
quate fluid secretion will have increased mucus 
concentrations and accumulation on airway sur-
faces. Accordingly, it may be useful in the future 
to assess the effects of inflammatory pathways 
in airway epithelia that have this phenotype.
Second, inflammation of the airways often 
occurs in hypoxic environments. Given the high 
partial pressure of oxygen in airway lumens, it 
may seem counterintuitive that inflammation 
and infection of airway mucus may be manifest 
in a hypoxic environment. However, because air-
way epithelia normally obtain oxygen from the 
lumen, the long diffusion distances imparted by 
mucus plaques render both plaques and airway 
epithelia hypoxic. Thus, future studies of inflam-
matory pathways might benefit from perfor-
mance under hypoxic and normoxic conditions.
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